Understand Contract Packaging: Five Stages That Define a Successful Partnership
“Getting the right product to the right patient on time is sometimes a different story than only focusing on the actual packaging specification.”
Pieter Cervruysse, VP Customer Success & Supply Chain, Tjoapack
Pharmaceutical packaging is not a single event, but a structured process that begins long before a product reaches a filling line and extends beyond the moment it leaves a packaging facility. Companies that treat it as a straightforward procurement step tend to discover, at some cost, that it isn’t.
The contract packaging process involves multiple stages, each with its own requirements, dependencies, and decision points. Getting one wrong affects everything that follows. Understanding the full sequence is the foundation of a well-managed outsourcing engagement.
This article walks through the five core stages of pharmaceutical contract packaging: from initial consultation through solution design, technology transfer, production and quality assurance, and into the ongoing supply relationship. At each stage, the decisions made — and the quality of information available to make them — determine whether a project delivers on time, on specification, and in compliance.
Stage 1: Initial Consultation — Defining What You Actually Need
The consultation stage exists to close a gap that is often present at the start of a packaging engagement: the gap between initial requirements and what a fuller picture of the project makes achievable.
Companies typically approach a contract packager with a brief built around internal assumptions. Those assumptions cover packaging format, batch size, timeline, and regulatory pathway. Many of them are reasonable. Some are not, and the ones that aren’t tend to surface later in the process — when correcting them is significantly more disruptive than addressing them upfront.
A well-run initial consultation covers product characteristics and format requirements, target markets and their specific regulatory obligations, supply chain origin and structure, timeline constraints, and the patient experience. For products intended for self-administration or use outside a clinical setting — autoinjectors, combination devices, patient-managed therapies — packaging design has a direct bearing on adherence and safety outcomes. Those considerations belong in the consultation, not as an afterthought in design.
The consultation also establishes which stakeholders need to be aligned. Packaging decisions touch procurement, quality, regulatory affairs, and commercial teams. Misalignment between those functions — different assumptions about format, timeline, or market scope — creates friction at later stages when it is far harder to resolve.
“What we often see is that the final solution we come up with is not the one that the customer asked for in the beginning. The scoping, the feasibility — what are you actually looking for? Having that initial conversation is really important.”
Pieter Ceurvuysse, VP Customer Success & Supply Chain, Tjoapack
That gap between the initial request and the eventual solution is not a failure of competence on either side. It is what a thorough discovery process is supposed to surface. A packaging partner that accepts a brief without challenging it is not doing its job.
Stage 2: Solution Design — Translating Requirements into a Workable Specification
Once the requirements are properly understood, solution design translates them into a defined packaging specification. This covers primary and secondary packaging formats, materials selection, artwork design, serialization strategy, and an assessment of whether existing production lines can support the specification or whether validation work will be needed.
Regulatory requirements by market are mapped in detail at this stage. Serialization formats, labeling language, importation testing obligations, and qualified person (QP) release requirements vary significantly across the EU, US, and other regulated markets. The EU Falsified Medicines Directive mandates specific serialization and tamper-evidence requirements. The US Drug Supply Chain Security Act imposes its own track-and-trace obligations. Products launching simultaneously across multiple markets must satisfy all of them — in some cases, with different packaging configurations for different jurisdictions.
Patient-centric design is not a secondary consideration. For combination products, self-administration devices, and formats used outside clinical settings, the packaging specification must account for how a patient will actually interact with the pack: ease of opening, label legibility, device ergonomics, and the practical realities of home or community administration. Packaging that works in a clinical trial setting does not always work for the patient population it is ultimately designed to serve.
The output of solution design is a fully scoped specification, priced and documented, with any required validation activities identified. It is also the stage at which a capable packaging partner raises feasibility concerns — and proposes alternatives where the original specification cannot be achieved within the requested parameters.
Stage 3: Technology Transfer — Building and Validating the Process
Technology transfer is the transition from agreed specification to operational readiness. It is the stage at which the packaging process is formally established, equipment is configured or validated, and supply chain integration is confirmed. For straightforward projects with well-established formats, transfer can move quickly. For novel products, complex multi-market requirements, or non-standard formats, it demands considerably more.
Process validation (confirming that the packaging process consistently produces a product meeting its specification) is a regulatory requirement, not an internal quality measure. Transport validation studies may also be required, particularly for temperature-sensitive products or those traveling long supply chain distances before reaching the packaging facility. For products manufactured in Asia or other lower-cost regions destined for EU or US markets, importation testing and identity testing obligations add further steps to the transfer sequence.
Readiness on the client side is a critical determinant of success alongside the packager’s technical capability. Companies that enter technology transfer with complete and accurate product documentation, clearly defined regulatory requirements for each target market, aligned quality expectations, and established supply chain routing typically progress more efficiently and with fewer iterations. Gaps in information, whether in specifications, artwork, serialization data, or compliance requirements, can introduce delays, increase risk, and extend project timelines.
Late-stage changes to artwork or regulatory requirements are among the most disruptive events in pharmaceutical packaging projects, as they can trigger re-approval cycles, material obsolescence, and potential revalidation, while also introducing regulatory and supply chain risks. Proactive communication between the packaging partner’s regulatory team and the client’s quality and regulatory affairs functions is the primary mechanism for preventing this.
“One of the most common challenges is a gap in information — or when, at a later stage, the regulatory or artwork change comes in very last minute, when we are almost there. Then we need to either go back to stage one or redesign the artwork from the beginning.”
Diana Orozco, Team Leader Customer Success, Tjoapack
Stage 4: Production and Quality Assurance
Production is where the process delivers output. In pharmaceutical packaging, that output is inseparable from the compliance framework governing its release. Every batch is subject to documented quality controls, in-process checks, and release procedures that form part of the regulatory record for the product.
Primary packaging operations (those involving direct contact with the drug product) require controlled cleanroom environments, typically ISO 7 or ISO 8 conditions (EU GMP Grade C/D). Maintaining those conditions consistently, across variable batch sizes and multiple product types, is a material operational capability. Not all contract packagers deliver it equally. Qualification of cleanroom environments, personnel gowning procedures, environmental monitoring, and contamination control protocols are the baseline conditions for regulatory compliance.
Quality management runs in parallel with manufacturing, not after it. Batch documentation, in-process controls, deviation identification and management, and statistical process monitoring are active functions throughout production. Deviations identified and managed during manufacturing are a normal part of pharmaceutical production. Deviations discovered after batch release are significantly more costly and time consuming.
“We are proactive in our communication towards our customers. Of course, we have a fully compliant quality management system, but whenever there are issues or whenever we see gaps proactively, we discuss them with our customers so that, in collaboration with the customer, things get done.”
Diana Orozco, Team Leader Customer Success, Tjoapack
Market release involves more than production sign-off. QP certification, serialization verification, importation testing for third-country products entering regulated markets, and market-specific documentation all form part of the release sequence. A packaging partner whose quality infrastructure is built around these obligations rather than retrofitted to them reduces the risk of delays at the release stage.
Stage 5: Ongoing Partnership — Supply Management and Continuous Improvement
Commercial supply is not a steady state. Demand fluctuates. Regulatory requirements update. Products enter new markets. Formats evolve in response to patient feedback or commercial decisions. The contract packaging relationship that works well at launch needs to be adaptable, and the characteristics that matter most in a long-term partner are different from those that matter most in a project partner.
“Once the product has been packed, we assure our customers and guide them through until their truck leaves our premises. Only then is our journey finished.”
Diana Orozco, Team Leader Customer Success, Tjoapack
Ongoing supply chain management involves scheduling, inventory coordination, lead time management, and responsiveness to demand variation. For multi-market products, it also involves staying current with serialization requirements, labeling obligations, and importation rules that change with regulatory updates — and ensuring those changes are reflected in the packaging process before they affect compliance.
Continuous improvement is the operational expression of a mature partnership. Regular review of production data, batch performance, and deviation trends allows packaging processes to be refined over time. A packager that surfaces this data proactively and uses it to inform process changes delivers more value over the commercial lifecycle of a product than one that simply executes the agreed specification batch after batch.
Continuity of account management is a practical consideration that is often underweighted in partner selection. When issues arise — supply disruptions, regulatory changes, quality events — the ability to reach a named contact with full knowledge of the product and its history shortens resolution time significantly. Named account managers, defined escalation paths, and documented project histories are operational infrastructure.
Critical Decision Points: Where Projects Succeed or Fail
Across the five stages, a small number of decision points consistently determine project outcomes. They are worth identifying explicitly.
Completeness of the initial brief. The quality of the consultation sets the ceiling for everything that follows. Accurate information about product characteristics, target markets, supply chain structure, and timeline constraints at the consultation stage translates directly into a more accurate solution design, and fewer expensive revisions later.
Partner selection criteria. Technical capability and price are necessary but insufficient criteria for selecting a contract packaging partner. How a partner manages communication, handles deviations, escalates problems, and supports clients through non-standard situations matters as much as what their equipment can do. These characteristics are visible in reference checks, facility audits, and the quality of the consultation itself.
Technology transfer readiness. Both parties must be ready. Clients who have completed required documentation, resolved supply chain routing, and confirmed their regulatory obligations for each target market move through transfer faster. Those who haven’t create delays that compound through the production schedule.
Change management discipline. Late changes to artwork, formulation, or regulatory requirements are a fact of pharmaceutical development. How they are identified, communicated, and managed determines whether they affect the project timeline or are absorbed without disruption. Clear change control processes, agreed at the outset, are the mechanism for managing this.
The Case for Early Engagement
The companies that navigate contract packaging most effectively share a common approach: they engage a packaging partner early and they treat the engagement as a collaborative process rather than a procurement transaction.
Early engagement creates options. A specialist partner brought in during product development can advise on packaging format before the specification is fixed, identify regulatory constraints before they affect the timeline, and contribute patient-centric design thinking before the solution is locked. A partner engaged after a problem has already materialized is constrained from the start.
The structure of the five-stage process is itself an argument for early engagement. Each stage depends on the quality of the one before it. Consultation shapes solution design. Solution design shapes technology transfer. Transfer shapes production. Production shapes the ongoing supply relationship. Compressing or shortcutting the early stages does not save time, but borrows it from the later ones, where the cost of correcting errors is higher.
For pharmaceutical and biotech companies building or revising their packaging strategy, understanding this process in full, and selecting partners on the basis of their capability across all five stages, not just the immediate one, is the most reliable path to packaging that supports rather than constrains the supply chain.
This article was produced in partnership with Tjoapack, a specialist contract packaging organization for pharmaceutical and biotech companies. With facilities in Europe (Netherlands) and the US (Tennessee), Tjoapack offers end-to-end packaging solutions from clinical to commercial supply.